Breakthrough Non-Invasive Cardiac Hemodynamics
Physicians treating patients suffering from chronic disease such
as heart failure and end stage renal disease (ESRD) today, have
few available options to measure central venous pressure (CVP),
central venous oxygenation, and cardiac output. Today’s
measurement and treatment methods are limited, expensive
and painful, putting already critically ill individuals at further risk. Mespere
Lifesciences is disrupting the marketplace with a revolutionary medical device
that can transform the way cardiac hemodynamics is measured today.
An estimated 80 million Americans have one or more types of cardiovascular disease (CVD). Nearly 2,400 Americans die of cardiovascular disease each day. That is an average of one death every 37 seconds.
A Pain Free and Reliable Way to Assess Volume Status
Mespere Lifesciences’ CVP monitor allows physicians to
non-invasively assess volume status of patients suffering from renal
diseases and congestive heart failure, and ultimately improve patient
outcomes.